Meeting
2023 ASCO Annual Meeting
Real-world multicentre analysis of patients with hepatocellular carcinoma (HCC) treated with atezolizumab and bevacizumab (A+B): Efficacy, esophagogastroduodenoscopy (EGD) uptake and bleeding complications.
Authors
Cha Len Lee
Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada
Cha Len Lee , Mark Freeman , Conor O'Donnell , Gordon Taylor Moffat , Ekaterina Kosyachkova , Hanna Lyubetska , Brandon M. Meyers , Vallerie Lynn Gordon , Philip Q. Ding , Aileigh Kay , Roxana Bucur , Winson Y. Cheung , Jennifer J. Knox , Vincent C. Tam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Advanced/Metastatic Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4105)
DOI
10.1200/JCO.2023.41.16_suppl.4105
Abstract #
4105
Poster Bd #
426
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study.
First Author: Kazuomi Ueshima
Poster
2021 ASCO Annual Meeting
IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study.
First Author: Valeriy Vladimirovich Breder
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase II study of atezolizumab and bevacizumab combination therapy for patients with advanced hepatocellular carcinoma who previously received systemic treatment.
First Author: Takeshi Terashima
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Achievement of cancer- and treatment-free status by atezolizumab plus bevacizumab combined with or without curative conversion in patients with transarterial chemoembolization-unsuitable, intermediate-stage hepatocellular carcinoma: A multicenter cohort study.
First Author: Masatoshi Kudo